Fresenius Medical Care AG

BIT:1FME Stock Report

Market Cap: €12.2b

Fresenius Medical Care Valuation

Is 1FME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1FME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1FME (€41.73) is trading below our estimate of fair value (€133.88)

Significantly Below Fair Value: 1FME is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1FME?

Key metric: As 1FME is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1FME. This is calculated by dividing 1FME's market cap by their current earnings.
What is 1FME's PE Ratio?
PE Ratio18.6x
Earnings€658.94m
Market Cap€12.23b

Price to Earnings Ratio vs Peers

How does 1FME's PE Ratio compare to its peers?

The above table shows the PE ratio for 1FME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.5x
AMP Amplifon
34.3x17.6%€5.3b
SRI Servizi Italia
14.8x16.9%€69.0m
DIA DiaSorin
29.5x13.6%€5.6b
DVA DaVita
15.6x4.3%US$13.1b
1FME Fresenius Medical Care
18.6x19.3%€12.2b

Price-To-Earnings vs Peers: 1FME is good value based on its Price-To-Earnings Ratio (18.6x) compared to the peer average (23.5x).

Price to Earnings Ratio vs Industry

How does 1FME's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
1FME 18.6xIndustry Avg. 18.6xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1FME is expensive based on its Price-To-Earnings Ratio (18.6x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is 1FME's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1FME PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.6x
Fair PE Ratio31.3x

Price-To-Earnings vs Fair Ratio: 1FME is good value based on its Price-To-Earnings Ratio (18.6x) compared to the estimated Fair Price-To-Earnings Ratio (31.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1FME forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€41.73
€39.82
-4.6%
18.5%€60.00€29.00n/a18
Nov ’25€36.55
€39.35
+7.7%
18.5%€60.00€29.00n/a18
Oct ’25€38.35
€38.85
+1.3%
20.1%€60.00€26.00n/a18
Sep ’25€34.90
€38.79
+11.2%
20.1%€60.00€26.00n/a18
Aug ’25€34.58
€39.03
+12.9%
19.6%€60.00€26.00n/a18
Jul ’25€35.89
€39.97
+11.4%
18.2%€58.50€26.00n/a19
Jun ’25€39.23
€39.92
+1.8%
18.3%€58.50€26.00n/a19
May ’25€39.81
€39.16
-1.6%
18.5%€58.50€26.00n/a19
Apr ’25€35.71
€38.95
+9.1%
19.2%€58.50€26.00n/a19
Mar ’25€35.61
€40.83
+14.7%
25.8%€73.00€26.00n/a20
Feb ’25€35.80
€40.68
+13.6%
25.8%€71.00€24.00n/a20
Jan ’25€37.82
€41.85
+10.6%
26.1%€71.00€24.00n/a19
Dec ’24€36.74
€41.90
+14.0%
26.0%€71.00€24.00n/a19
Nov ’24€31.34
€43.21
+37.9%
21.6%€60.00€24.00€36.5518
Oct ’24€41.36
€44.67
+8.0%
22.3%€67.00€24.00€38.3518
Sep ’24€44.94
€44.51
-1.0%
22.3%€67.00€24.00€34.9019
Aug ’24€47.19
€40.92
-13.3%
27.3%€67.00€21.00€34.5818
Jul ’24€43.60
€38.16
-12.5%
27.9%€67.00€21.00€35.8917
Jun ’24€40.00
€36.99
-7.5%
31.2%€67.00€17.40€39.2317
May ’24€43.60
€35.90
-17.7%
32.2%€67.00€17.40€39.8116
Apr ’24€38.60
€34.08
-11.7%
33.2%€67.00€17.40€35.7116
Mar ’24€35.50
€33.39
-5.9%
34.9%€67.00€17.40€35.6115
Feb ’24€35.05
€32.78
-6.5%
36.0%€67.00€17.10€35.8015
Jan ’24€30.17
€34.12
+13.1%
33.3%€67.00€17.10€37.8215
Dec ’23€30.00
€34.27
+14.2%
34.3%€67.00€17.10€36.7414
Nov ’23€27.30
€37.37
+36.9%
32.1%€67.00€17.10€31.3415

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Amplifon

€5.3b

Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.

AMP

€23.68

7D

-6.1%

1Y

-15.9%

Garofalo Health Care

€511.9m

Operates healthcare clinics in Italy.

GHC

€5.78

7D

5.9%

1Y

23.8%

Servizi Italia

€69.0m

Provides wash-hire and sterilization services in Italy, Turkey, and Brazil.

SRI

€2.37

7D

0%

1Y

46.3%